Evidence map›Paper›PMID 41511532›Full record

GuidelineHerz2026

[ESC guidelines on myocarditis and pericarditis : First combined European guidelines for myocarditis and pericarditis].

Bernhard Maisch, Jan Gröschel, Bettina Heidecker, Jeanette Schulz-Menger

Abstract readEnglish AbstractPractice Guideline
In one paragraph

Guideline in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bernhard MaischHerz- und Gefäßzentrum Marburg und Medizinische Fakultät, Philipps-Universität Marburg, Marburg, Deutschland.
Jan GröschelCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Deutschland.
Bettina HeideckerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Deutschland.
Jeanette Schulz-MengerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Deutschland. jeanette.schulz-menger@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new guidelines for myocarditis and pericarditis from the European Society of Cardiology (ESC) are the first guidelines for myocarditis and for the first time they also combine the two entities. A key aspect is the introduction of the term inflammatory myopericardial syndrome (IMPS), an umbrella term that covers the spectrum of both diseases and enables uniform diagnostics and treatment but in particular draws attention to the fact that there are overlapping causes, diagnostic approaches and treatment options. Other major aspects relate to noninvasive diagnostics using multimodal imaging. There is a paradigm shift that enables the definitive diagnosis of myocarditis also using cardiovascular magnetic resonance imaging. An etiologically oriented treatment mostly requires an endomyocardial biopsy in pericardial effusion cytological work-up is instrumental. Furthermore, an intuitive risk stratification is introduced, which influences both the treatment and follow-up examinations and involves abandoning fixed waiting periods with respect to resuming sports and work. Diagnostic algorithms are based on the initial symptoms, such as chest pain, heart failure and arrhythmia and integrate the risk stratification into the treatment process. For pericarditis, innovative treatment approaches using interleukin‑1 antagonists are coming to the fore. Another focus is the consideration of genetic factors, which are particularly relevant in recurrent forms.

Indexed as

CardiologyMyocarditisPericarditisEuropeEvidence-Based MedicineHumansCardiovascular magnetic resonanceEndomyocardial biopsyGenetic factorsInflammatory myopericardial syndromeInterleukin‑1 antagonists

Identifiers

PMID41511532
PMCPMC12855212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.